fig1
![Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment](https://image.oaes.cc/51cf190d-d312-48af-80da-ca0b6bab0d9f/3075.fig.1.jpg)
Figure 1. The cumulative recurrence rate in patients treated with DAAs after curative treatment for HCC. HCC recurred in 135 patients. The 1-, 2- and 3-year cumulative recurrence rates after DAA therapy were 18%, 39% and 55%, respectively. HCC: hepatocellular carcinoma; DAA: direct-acting antiviral